Akcea is developing treatments for unaddressed or under-addressed serious and rare diseases with leading-edge, RNA-targeted medicines.
Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company primarily focused on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated ...
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, ...
Develops Enhanced CrossLinking and Immunoprecipitation (eCLIP), followed by high-throughput sequencing (eCLIP-seq), to identify RNA transcripts bound in vivo by a protein of interest.
mRNA based medicines for rare diseases
enGene Inc. has developed a highly flexible nucleotide (DNA and RNAi) delivery technology that targets mucosal tissues and can be used to treat numerous prevalent, chronic diseases via the ...
Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technologies. Their integrated platform enables the discovery, design and development of ...
Greenlight Biosciences uses a cell-free production platform to develop RNA products for plant and life science applications.
Multivalent RNAi Platform, Delivery
Gene therapy requires delivery. Ligandal has developed a breakthrough nanotechnology for the precise and high-efficiency delivery of nucleic acids (CRISPR, TALEN, and RNA) to specific cells and ...
RNA Profiling and Services
Gene Expression and miRNA Expression, NGS, qPCR and Genomic Data Analysis
A biopharmaceutical company developing a portfolio of mRNA products to correct inherited, life-threatening liver diseases in children.